TAS-102 vs. placebo with best supportive care in refractory patients with met colorectal cancer
Speaker: Josep Tabernero
In this video, Josep Tabernero discusses:
- What is TAS-102 and how it works?
- What are preclinical and early clinical findings with TAS-102?
- Design and results of RECOURSE study in patients with metastatic colorectal cancer refractory to standard therapies.